Lung epithelium model being tested as a platform for COVID-19 research – Drug Target Review

The developers of the lung epithelium model plan to investigate whether SARS-CoV-2 can infect and replicate in the model to assess whether it could be used in the fight against COVID-19. A biotech company has announced they are testing whether their human lung epithelium model could be used as a platform for investigating SARS-CoV-2 infection and developing and evaluating potential antiviral strategies for COVID-19. Newcells Biotech based their lung epithelium organoid on human induced pluripotent stem cells (hiPSC) and have been developing the model for two years.

Read more
Facilitating Drug Discovery With Induced Pluripotent Stem Cells – News-Medical.net

Download Axols free white paper - "Induced Pluripotent Stem Cells: recapitulating disease to facilitate drug discovery" Understand more about how iPSC-derived cells can improve any drug development research program by supplying a physiologically relevant model, which is capable of representing a disease population. This enables research in multiple stages of the development pipeline. This white paper comprises cases wherein iPSC-derived cells have been utilized for target identification, target validation, lead optimization and safety testing, as a means of reducing failure rates of drug candidates.

Read more
Europe midday: Stocks track gains on Wall Street, drug and biotech shares higher – ShareCast

Stocks in the rest of Europe were putting in a small bounce on Tuesday, with investors taking their cue from US markets, which had finished higher the day before on the hope that the worst scenarios in the Middle East could yet be averted. That was despite the head of Iran's national security council, Ali Shamkhani's, reported threat of a "historic nightmare" for the US. "Even though tensions between the US and Iran remain high, sentiment in equity markets has turned positive, as European indices are showing modest gains this morning

Read more